Blueprint Medicines to Present at Upcoming Investor Conferences - Feb. 19, 2020

CAMBRIDGE, Mass., Feb. 19, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation in fireside chats at the following upcoming investor conferences:


  • 9th Annual SVB Leerink Global Healthcare Conference in New York, NY on Wednesday, February 26, 2020 at 9:00 a.m. ET.
  • 40th Annual Cowen Health Care Conference in Boston, MA on Tuesday, March 3, 2020 at 12:00 p.m. ET.

A live webcast of each presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at A replay of the webcasts will be archived on Blueprint Medicines' website for 30 days following each presentation.

About Blueprint Medicines

Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We have one precision therapy approved by the U.S. Food and Drug Administration and are currently advancing multiple investigational medicines in clinical development, along with a number of research programs. For more information, visit and follow us on Twitter (@BlueprintMeds) and LinkedIn.

Cision View original content to download multimedia:

SOURCE Blueprint Medicines Corporation

Company Codes: NASDAQ-NMS:BPMC

Back to news